Mont

The term "Mont" is used in the provided context to refer to multiple distinct entities. It is an abbreviation for **Montelukast**, a pharmaceutical medication primarily used to treat chronic obstructive pulmonary disease (COPD). Montelukast has been investigated in combination with clarithromycin for its potential to suppress the progression of aortic aneurysms in a murine model of COPD, where it demonstrated effects such as reduced inflammation, preserved elastin, and increased infiltrated M2 macrophages. Additionally, "Mont" refers to **Montmorillonite (MONT)**, a phyllosilicate layered mineral. Montmorillonite is studied for its in vivo ability to reduce protein intestinal uptake in healthy volunteers and is utilized for therapeutic purposes, in pharmaceutical formulations, and in food preparations. It has also been incorporated into antimicrobial coating films for denture lining materials. Furthermore, "MONT" is used to describe a **silver-based Metal-organic framework (Ag-MOF MONT)**, which has been developed for highly sensitive detection systems, particularly for procaterol.